Skip to main content
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Martin Shkreli violated lifetime pharma industry ban, FTC and states say

The filing says Shkreli traded 11 pharma stocks and used livestreams and social media to discuss the industry despite a lifetime ban.

  • On Tuesday, the Federal Trade Commission and seven states asked a federal judge to hold Martin Shkreli in contempt, alleging he "flagrantly and repeatedly violated" a 2022 court order banning him for life from the pharmaceutical industry.
  • The 2022 ban stemmed from an anti-competitive scheme involving Daraprim; Shkreli previously served more than four years in prison following a 2017 securities fraud conviction.
  • Filings indicate Shkreli violated the order by broadcasting trades on YouTube, including an account starting with $10 million that traded 11 stocks such as Pfizer and Moderna.
  • Daniel Guarnera, director of the FTC's Bureau of Competition, stated "when judgment is entered by a court, defendants must fulfill their obligations," as the agency seeks fines equivalent to profits from banned trades.
  • Beyond public trading, Shkreli has claimed to maintain undisclosed accounts, telling viewers during a livestream that he avoids showing them because "I know feds are watching.
Insights by Ground AI
Podcasts & Opinions

45 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 53% of the sources are Center
53% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Reuters broke the news in London, United Kingdom on Tuesday, October 13, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal